CAJ | 학술논문

目的：建立狂犬病病毒固定毒CTN-1V株在人二倍体细胞Walvax-2株上的传代适应株。方法用狂犬病病毒固定毒CTN-1V株经昆明小鼠鼠脑回传后的病毒接种Walvax-2细胞，连续传代，检测各代次病毒的滴度及免疫原性。结果 CTN-1V株能较好地适应Walvax-2细胞，通过连续带毒传代至第7代，病毒滴度可达6．78 lg LD50/mL，并在第10～15代内滴度维持在7．0 lg LD50/mL以上，15～30代滴度稳定在7．0 lg LD50/mL左右。以15代适应毒株CTN-1V-HDC P15制备的疫苗原液，各项指标均符合《中华人民共和国药典》三部（2010版）的要求，疫苗效力在6．0 IU/剂以上。结论所获人胚肺二倍体细胞Walvax-2株传代适应狂犬病毒固定毒株CTN-1V-HDC可用于人用狂犬病疫苗的生产开发。
목적：건립광견병병독고정독CTN-1V주재인이배체세포Walvax-2주상적전대괄응주。방법용광견병병독고정독CTN-1V주경곤명소서서뇌회전후적병독접충Walvax-2세포，련속전대，검측각대차병독적적도급면역원성。결과 CTN-1V주능교호지괄응Walvax-2세포，통과련속대독전대지제7대，병독적도가체6．78 lg LD50/mL，병재제10～15대내적도유지재7．0 lg LD50/mL이상，15～30대적도은정재7．0 lg LD50/mL좌우。이15대괄응독주CTN-1V-HDC P15제비적역묘원액，각항지표균부합《중화인민공화국약전》삼부（2010판）적요구，역묘효력재6．0 IU/제이상。결론소획인배폐이배체세포Walvax-2주전대괄응광견병독고정독주CTN-1V-HDC가용우인용광견병역묘적생산개발。
Objective To develop a rabies virus fixed virus adaption strain on human embryo lung diploid cell strain Walvax -2.Methods The rabies fixed virus strain ,CTN-1V,was inoculated in Kunming mice brains ,followed by being continuously passaged in Walvax-2 cells,titers for all passages and immunogenicity for every 5 passages were detected .Resutl s CTN-1V strain can adapte to human diploid Walvax-2 cell.By continuously passaging in Walvax-2 strain,the virus titer reached 6.88 lg LD50/mL at 9th passage,maintained above 7.0 lg LD50/mL from 10th to 15th passages,and stabilized around 7.0 lg LD50/mL from 15th to 30th passages.All indicators of the vaccine bulk prepared from virus adaption strain CTN-1V-HDC P15 met the requirements of “Chinese Pharmacopeia” volume III( 2010 edition), all of vaccine efficacy were above 6.0 IU/dose. Conclusion The developed rabies virus strain CTN-1V-HDC, adapted and passaged on human embryo lung diploid cell strain Walvax-2 ,can be used in development and production of human rabies vaccine .